Cited by 458Alzheimer's disease research and treatmentsCholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment Research

The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Open access

Brunden, Kurt R., Trojanowski, John Q., Lee, Virginia M.-Y.·2009·Nature Reviews Drug Discovery

DOI 10.1038/nrd2959PMC PMC2787232

Open this paper in CoChat — free account

Abstract

Neuronal inclusions comprised of the microtubule-associated protein tau are found in numerous neurodegenerative diseases, commonly known as tauopathies. In Alzheimer's disease - the most prevalent tauopathy - misfolded tau is probably a key pathological agent. The recent failure of amyloid-beta-targeted therapeutics in Phase III clinical trials suggests that it is timely and prudent to consider alternative drug discovery strategies for Alzheimer's disease. Here, we focus on strategies directed at reducing misfolded tau and compensating for the loss of normal tau function.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/nrd2959

Cites

140 of 140 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease
Arriagada, P. V., Growdon, J. H., Hedley-Whyte, E. T., & Hyman, B. T. (1992) · Neurology · doi:10.1212/wnl.42.3.631 · Cited by 2,668
Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease
Goedert, M., Spillantini, M. G., Jakes, R., Rutherford, D., & Crowther, R. A. (1989) · Neuron · doi:10.1016/0896-6273(89)90210-9 · Cited by 2,492
Neurodegenerative Tauopathies
Lee, V. M.-Y., Goedert, M., & Trojanowski, J. Q. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1121 · Cited by 2,480
Self-citation
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174
Self-citation
Tau protein isoforms, phosphorylation and role in neurodegenerative disorders11These authors contributed equally to this work.
Buée, L., Bussière, T., Buée‐Scherrer, V., Delacourte, A., & Hof, P. R. (2000) · Brain Research Reviews · doi:10.1016/s0165-0173(00)00019-9 · Cited by 2,133
Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function
SantaCruz, K., Lewis, J., Spires, T., Paulson, J., Kotilinek, L., Ingelsson, M., Guimaraes, A., DeTure, M., Ramsden, M., McGowan, E., et al. (2005) · Science · doi:10.1126/science.1113694 · Cited by 2,014
Reducing Endogenous Tau Ameliorates Amyloid ß-Induced Deficits in an Alzheimer's Disease Mouse Model
Roberson, E. D., Scearce-Levie, K., Palop, J. J., Yan, F., Cheng, I. H., Wu, T., Gerstein, H., Yu, G.-Q., & Mucke, L. (2007) · Science · doi:10.1126/science.1141736 · Cited by 1,892
Extensive Involvement of Autophagy in Alzheimer Disease: An Immuno-Electron Microscopy Study
Nixon, R. A., Wegiel, J., Kumar, A., Yu, W. H., Peterhoff, C., Cataldo, A., & Cuervo, A. M. (2005) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/64.2.113 · Cited by 1,588
The distribution of tau in the mammalian central nervous system.
Binder, L. I., Frankfurter, A., & Rebhun, L. I. (1985) · The Journal of cell biology · doi:10.1083/jcb.101.4.1371 · Cited by 1,588

Flagged first, then by citations

Show all 140 references

Research works printed but not linked: 3

Avila, J. Tau and tauopathies: tau phosphorylation and tau assembly. FEBS J. 273, 23 (2006).
Alonso, A. D., GrundkeIqbal, I. & Iqbal, K. Abnormally phosphorylated tau from Alzheimer disease brain depolymerizes microtubules. Neurobiol. Aging 15, S37 (1994).
Schneider, A., Biernat, J., von Bergen, M., Mandelkow, E. & Mandelkow, E. M. Phosphorylation that detaches tau from microtubules S262 and S214 protects it against aggregation into Alzheimer paired helical filaments. J. Neurochem. 73, S26 (1999).

Sorted by citations

Items 201–300 of 458

Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer’s disease
Yu, M., Risacher, S. L., Nho, K. T., Wen, Q., Oblak, A. L., Unverzagt, F. W., Apostolova, L. G., Farlow, M. R., Brosch, J. R., Clark, D. G., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113691 · Cited by 36
Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, That Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy
Chen, P. C., Gaisina, I. N., El‐Khodor, B. F., Ramboz, S., Makhortova, N. R., Rubin, L. L., & Kozikowski, A. P. (2011) · ACS Chemical Neuroscience · doi:10.1021/cn200085z · Cited by 34
Microtubule assembly by tau impairs endocytosis and neurotransmission via dynamin sequestration in Alzheimer’s disease synapse model
Hori, T., Eguchi, K., Wang, H.-Y., Miyasaka, T., Guillaud, L., Taoufiq, Z., Mahapatra, S., Yamada, H., Takei, K., & Takahashi, T. (2022) · eLife · doi:10.7554/elife.73542 · Cited by 34
Tolfenamic acid reduces tau and CDK 5 levels: implications for dementia and tauopathies
Adwan, L. I., Subaiea, G. M., Basha, R. M., & Zawia, N. H. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12960 · Cited by 34
Liquid-liquid phase separation in Alzheimer’s disease
Fu, Q., Zhang, B., Chen, X., & Chu, L. (2024) · Journal of Molecular Medicine · doi:10.1007/s00109-023-02407-3 · Cited by 33
Understanding the relationship between GSK-3 and Alzheimer’s disease: a focus on how GSK-3 can modulate synaptic plasticity processes
Medina, M., & Ávila, J. (2013) · Expert Review of Neurotherapeutics · doi:10.1586/ern.13.39 · Cited by 33
Aminothienopyridazine inhibitors of tau aggregation: Evaluation of structure–activity relationship leads to selection of candidates with desirable in vivo properties
Ballatore, C., Crowe, A., Piscitelli, F., James, M., Lou, K., Rossidivito, G., Yao, Y., Trojanowski, J. Q., Lee, V. M. ‐., Brunden, K. R., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.027 · Cited by 32
Self-citation
Frontiers in Alzheimer’s disease therapeutics
Stone, J. G., Casadesús, G., Rothenberg, K. G., Siedlak, S. L., Wang, X., Zhu, X., Perry, G. L., Castellani, R. J., & Smith, M. A. (2010) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622310382817 · Cited by 32
Mechanistic Insights into Selective Autophagy Subtypes in Alzheimer’s Disease
Guan, X., Iyaswamy, A., Sreenivasmurthy, S. G., Su, C.-F., Zhu, Z., Liu, J., Kan, Y., Cheung, K., Lu, J., Tan, J., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073609 · Cited by 32
Alzheimer’s Disease: Lessons Learned from Amyloidocentric Clinical Trials
Soejitno, A., Tjan, A., & Purwata, T. E. (2015) · CNS Drugs · doi:10.1007/s40263-015-0257-8 · Cited by 32
Discovery of novel 2-(alkylmorpholin-4-yl)-6-(3-fluoropyridin-4-yl)-pyrimidin-4(3H)-ones as orally-active GSK-3β inhibitors for Alzheimer’s disease
Fukunaga, K., Sakai, D., Watanabe, K., Nakayama, K., Kohara, T., Tanaka, H., Sunada, S., Nabeno, M., Okamoto, M., Saito, K.-I., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.01.005 · Cited by 32
Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells
Wilmes, A., O’Sullivan, D., Chan, A. H. L., Chandrahasen, C., Paterson, I., Northcote, P. T., Flamme, A. C. L., & Miller, J. H. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1461-3 · Cited by 32
T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice
Fukushima, T., Nakamura, A., Iwakami, N., Nakada, Y., Hattori, H., Hoki, S., Yamaguchi, H., Nakagawa, M., Terashima, N., & Narita, H. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.091 · Cited by 31
Alzheimer’s Disease: Characterization of the Brain Sites of the Initial Tau Cytoskeletal Pathology Will Improve the Success of Novel Immunological Anti-Tau Treatment Approaches
Rüb, U., Stratmann, K., Heinsen, H., Seidel, K., Bouzrou, M., & Korf, H. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161102 · Cited by 31
The novel calpain inhibitor A-705253 prevents stress-induced tau hyperphosphorylation in vitro and in vivo
Nikkel, A. L., Martino, B. R., Markosyan, S., Brederson, J., Medeiros, R., Möller, A., & Bitner, R. S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.011 · Cited by 30
Potential synergy between tau aggregation inhibitors and tau chaperone modulators
Blair, L. J., Zhang, B., & Dickey, C. A. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt207 · Cited by 30
Inhibition of Early Growth Response 1 in the Hippocampus Alleviates Neuropathology and Improves Cognition in an Alzheimer Model with Plaques and Tangles
Qin, X., Wang, Y., & Paudel, H. K. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.018 · Cited by 29
A novel organotypic tauopathy model on a new microcavity chip for bioelectronic label-free and real time monitoring
Krinke, D., Jahnke, H., Mack, T. G. A., Hirche, A., Striggow, F., & Robitzki, A. A. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.06.002 · Cited by 29
Cyanidin-3-O-glucoside attenuates amyloid-beta (1–40)-induced oxidative stress and apoptosis in SH-SY5Y cells through a Nrf2 mechanism
Meng, L., Li, B., Li, D.-N., Wang, Y., Lin, Y., Meng, X., Sun, X., & Liu, N. (2017) · Journal of Functional Foods · doi:10.1016/j.jff.2017.09.025 · Cited by 28
Alginate-Derived Mannuronate Oligosaccharide Attenuates Tauopathy through Enhancing Autophagy
Bi, D., Xiao, S., Lin, Z., Yao, L., Fang, W., Wu, Y. L., Xu, H. Y., Lu, J., & Xu, X. (2021) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.1c00394 · Cited by 28
Effects of Deferasirox in Alzheimer’s Disease and Tauopathy Animal Models
Kwan, P., Ho, A. S.-W., & Baum, L. (2022) · Biomolecules · doi:10.3390/biom12030365 · Cited by 28
Susceptibility to GSK3β-Induced Tau Phosphorylation Differs Between the Young and Aged Hippocampus after Wnt Signaling Inhibition
Salcedo‐Tello, P., Hernández‐Ortega, K., & Arias, C. (2014) · Journal of Alzheimer s Disease · doi:10.3233/jad-130749 · Cited by 28
The Structure Biology of Tau and Clue for Aggregation Inhibitor Design
Wang, D., Huang, X., Yan, L., Zhou, L., Chang, Y., Wu, J., Su, Z., & Huang, Y. (2021) · The Protein Journal · doi:10.1007/s10930-021-10017-6 · Cited by 27
Lipids and lipoproteins may play a role in the neuropathology of Alzheimer’s disease
Akyol, Ö., Akyol, S., Chou, M., Chen, S., Liu, C., Selek, S., Soares, J. C., & Chen, C. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1275932 · Cited by 27
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Sui, D., Liu, M., & Kuo, M. (2015) · Journal of Visualized Experiments · doi:10.3791/51537 · Cited by 28
Current Therapies and New Strategies for the Management of Alzheimer’s Disease
Aderinwale, O. G., Ernst, H. W., & Mousa, S. A. (2010) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317510372372 · Cited by 27
Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs
Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27
Protective Effects of Hydroxysafflor Yellow A on β-Amyloid-Induced Neurotoxicity in PC12 Cells
Kong, S., Xian, Y., Ip, S., Lai, X., Shi, X., Lin, Z., & Su, Z. (2013) · Neurochemical Research · doi:10.1007/s11064-013-1002-7 · Cited by 26
Small molecule targeting of RNA structures in neurological disorders
Angelbello, A. J., Chen, J. L., & Disney, M. D. (2019) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14051 · Cited by 26
The Cellular Distribution and Ser262 Phosphorylation of Tau Protein Are Regulated by BDNF In Vitro
Chen, Q., Zhou, Z., Zhang, L., Xu, S., Chen, C., & Yu, Z. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091793 · Cited by 26
Gene promoter methylation and expression of Pin1 differ between patients with frontotemporal dementia and Alzheimer's disease
Ferri, E., Arosio, B., D’Addario, C., Galimberti, D., Gussago, C., Pucci, M., Casati, M., Fenoglio, C., Abbate, C., Rossi, P. D., et al. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.02.004 · Cited by 26
Rational design of potent GSK3β inhibitors with selectivity for Cdk1 and Cdk2
Lesuisse, D., Dutruc-Rosset, G., Tiraboschi, G., Dreyer, M., Maignan, S., Chevalier, A., Halley, F., Bertrand, P., Burgevin, M., Quarteronet, D., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.01.114 · Cited by 26
Recent advances in tau-directed immunotherapy against Alzheimer’s disease: an overview of pre-clinical and clinical development
Ng, P. Y., Chang, I. S., Koh, R. Y., & Chye, S. M. (2020) · Metabolic Brain Disease · doi:10.1007/s11011-020-00591-6 · Cited by 25
Olfactory deficit is associated with mitral cell dysfunction in the olfactory bulb of P301S tau transgenic mice
Li, S., Li, W., Wu, X., Li, J., Yang, J., Tu, C., Ye, X., & Ling, S. (2019) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2019.03.006 · Cited by 25
Synthesis, Stereochemical Analysis, and Derivatization of Myricanol Provide New Probes That Promote Autophagic Tau Clearance
Martin, M. D., Calcul, L., Smith, C., Jinwal, U. K., Fontaine, S. N., Darling, A. L., Seeley, K. W., Wojtas, Ł., Narayan, M., Gestwicki, J. E., et al. (2015) · ACS Chemical Biology · doi:10.1021/cb501013w · Cited by 25
Identification of new BACE1 inhibitors for treating Alzheimer’s disease
Kushwaha, P., Singh, V., Somvanshi, P., Bhardwaj, T., Barreto, G. E., Ashraf, G. M., Mishra, B. N., Chundawat, R. S., & Haque, S. (2021) · Journal of Molecular Modeling · doi:10.1007/s00894-021-04679-3 · Cited by 24
Cerebrospinal fluid and blood biomarkers in the diagnostic assays of Alzheimer’s disease
Zhang, L., Liang, X., Zhang, Z., & Luo, H. (2021) · Journal of Innovative Optical Health Sciences · doi:10.1142/s1793545822300014 · Cited by 24
Demencia frontotemporal variante conductual: aproximación clínica y terapéutica
Fernández‐Matarrubia, M., Matías‐Guiu, J. A., Moreno‐Ramos, T., & Matías‐Guiu, J. (2013) · Neurología · doi:10.1016/j.nrl.2013.03.001 · Cited by 24
Ropren® is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25–35)-induced amnesia
Fedotova, J., Soultanov, V., Nikitina, T. V., Roschin, V., & Ordayn, N. (2012) · Phytomedicine · doi:10.1016/j.phymed.2011.09.073 · Cited by 24
Tau Protein Mediates APP Intracellular Domain (AICD)-Induced Alzheimer’s-Like Pathological Features in Mice
Ghosal, K., Fan, Q., Dawson, H. N., & Pimplikar, S. W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0159435 · Cited by 24
The sphingosine-1-phosphate receptor 1 agonist SEW2871 reduces Tau-Ser262 phosphorylation in rat hippocampal slices
Giguère, F. S.-C., Essis, S. A., Chagniel, L., Germain, M., Cyr, M., & Massicotte, G. (2017) · Brain Research · doi:10.1016/j.brainres.2017.01.014 · Cited by 24
HIV, prospective memory, and cerebrospinal fluid concentrations of quinolinic acid and phosphorylated Tau
Anderson, A. M. L., Croteau, D. J., Ellis, R. J., Cookson, D. R., Potter, M., Guillemin, G. J., Brew, B. J., Woods, S. P., & Letendre, S. L. (2018) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2018.03.007 · Cited by 24
Hallmark cellular pathology of Alzheimer’s disease induced by mutant human tau expression in cultured Aplysia neurons
Shemesh, O. A., & Spira, M. E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0689-7 · Cited by 24
Cellular Uptake of Mildly Oxidized Nanographene for Drug-Delivery Applications
Mugnano, M., Lama, G. C., Castaldo, R., Marchesano, V., Merola, F., del Giudice, D., Calabuig, A., Gentile, G., Ambrogi, V., Cerruti, P., et al. (2019) · ACS Applied Nano Materials · doi:10.1021/acsanm.9b02035 · Cited by 23
Compound screening in cell-based models of tau inclusion formation: Comparison of primary neuron and HEK293 cell assays
Crowe, A., Henderson, M. J., Anderson, J. D., Titus, S. A., Zakharov, A. V., Simeonov, A. M., Buist, A., Delay, C., Moechars, D., Trojanowski, J. Q., et al. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010532 · Cited by 23
Self-citation
Tau Interacting Proteins: Gaining Insight into the Roles of Tau in Health and Disease
Stancu, I., Ferraiolo, M., Terwel, D., & Dewachter, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9358-8_13 · Cited by 23
In Silico Drug Design and Analysis of Dual Amyloid-Beta and Tau Protein-Aggregation Inhibitors for Alzheimer’s Disease Treatment
Job, N., Thimmakondu, V. S., & Thirumoorthy, K. (2023) · Molecules · doi:10.3390/molecules28031388 · Cited by 23
Modulation of biomolecular phase behavior by metal ions
Sołtys, K., Tarczewska, A., & Bystranowska, D. (2023) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2023.119567 · Cited by 23
Selective activators of protein phosphatase 5 target the auto-inhibitory mechanism
Haslbeck, V., Drazic, A., Eckl, J. M., Alte, F., Helmuth, M., Popowicz, G. M., Schmidt, W., Braun, F., Weiwad, M., Fischer, G. S., et al. (2015) · Bioscience Reports · doi:10.1042/bsr20150042 · Cited by 23
Inhibition of Both Hsp70 Activity and Tau Aggregation in Vitro Best Predicts Tau Lowering Activity of Small Molecules
Martin, M. D., Baker, J. D., Suntharalingam, A., Nordhues, B. A., Shelton, L. B., Zheng, D., Sabbagh, J. J., Haystead, T., Gestwicki, J. E., & Dickey, C. A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00223 · Cited by 23
The ameliorative effects and underlying mechanisms of dopamine D1-like receptor agonist SKF38393 on Aβ 1–42 -induced cognitive impairment
Zang, X., Cheng, Z.-Y., Sun, Y., Hua, N., Zhu, L.-H., & He, L. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.09.017 · Cited by 23
Correlation between Cognitive Impairment and Peripheral Biomarkers - Significance of Phosphorylated Tau and Amyloid-β in Alzheimer’s Disease: A New Insight
Sarkar, S., Bhui, U., Kumar, B., Ashique, S., Kumar, P., Sharma, H., Bhowmick, M., Pal, R., & Kumar, T. (2024) · Current Psychiatry Research and Reviews · doi:10.2174/0126660822329981241007105405 · Cited by 25
Neurosteroids and Oxysterols as Potential Therapeutic Agents for Glaucoma and Alzheimer’s Disease
Ishikawa, M., Yoshitomi, T., Covey, D. F., Zorumski, C. F., & Izumi, Y. (2018) · Neuropsychiatry · doi:10.4172/neuropsychiatry.1000356 · Cited by 22
Rescue of tau-induced synaptic transmission pathology by paclitaxel
Erez, H., Shemesh, O. A., & Spira, M. E. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00034 · Cited by 22
Detection and Characterization of Small Molecule Interactions with Fibrillar Protein Aggregates Using Microscale Thermophoresis
Fisher, E., Zhao, Y., Richardson, R., Janik, M. A., Buell, A. K., Aigbirhio, F. I., & Tóth, G. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00228 · Cited by 22
Tolfenamic Acid: A Modifier of the Tau Protein and its Role in Cognition and Tauopathy
Chang, J. K., Leso, A., Subaiea, G. M., Lahouel, A., Masoud, A. M., Mushtaq, F., Deeb, R., Eid, A., Dash, M. E., Bihaqi, S. W., et al. (2018) · Current Alzheimer Research · doi:10.2174/1567205015666180119104036 · Cited by 22
Brain Damage - Bridging Between Basic Research and Clinics
González-Quevedo, A. (2012) · InTech eBooks · doi:10.5772/2174 · Cited by 21
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Cummings, J. L., & Zhong, K. (2013) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2013.205 · Cited by 21
14-3-3ζ Mediates Tau Aggregation in Human Neuroblastoma M17 Cells
Li, T., & Paudel, H. K. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160635 · Cited by 21
Tubulin modifying enzymes as target for the treatment of tau-related diseases
Rogowski, K., Hached, K., Crozet, C., & van der Laan, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107681 · Cited by 21
Exploring the conservation of Alzheimer-related pathways between H. sapiens and C. elegans: a network alignment approach
Apostolakou, A. E., Sula, X. K., Nastou, K. C., Nasi, G. I., & Iconomidou, V. A. (2021) · Scientific Reports · doi:10.1038/s41598-021-83892-9 · Cited by 21
Formaldehyde‐Crosslinked Nontoxic Aβ Monomers to Form Toxic Aβ Dimers and Aggregates: Pathogenicity and Therapeutic Perspectives
Zhao, H., Huang, X., & Tong, Z. (2021) · ChemMedChem · doi:10.1002/cmdc.202100428 · Cited by 21
RTN/Nogo in forming Alzheimer's neuritic plaques
Prior, M., Shi, Q., Hu, X., He, W., Levey, A. I., & Yan, R. (2010) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.01.017 · Cited by 21
High salt induces cognitive impairment via the interaction of the angiotensin II‐AT1 and prostaglandin E2‐EP1 systems
Kubota, H., Kunisawa, K., Wulaer, B., Hasegawa, M., Kurahashi, H., Sakata, T., Tezuka, H., Kugita, M., Nagao, S., Nagai, T., et al. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16093 · Cited by 20
Stressing Out Hsp90 in Neurotoxic Proteinopathies
Inda, C., Bolaender, A., Wang, T., Gandu, S. R., & Koren, J. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160413141350 · Cited by 20
Alzheimer Disease
Savonenko, A. V., Melnikova, T., Li, T., Price, D. L., & Wong, P. C. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-398270-4.00021-5 · Cited by 20
Inhibitors of heat shock protein 70 (Hsp70) with enhanced metabolic stability reduce tau levels
Shao, H., Li, X., Hayashi, S., Bertron, J. L., Schwarz, D. M. C., Tang, B. C., & Gestwicki, J. E. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.128025 · Cited by 20
Synthetic RNA Modulators in Drug Discovery
Zamani, F., & Suzuki, T. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00154 · Cited by 20
Expression and significance of plasma 3-NT and ox-LDL in patients with Alzheimer's disease
Zhao, Z., Zhou, H., Peng, Y., Qiu, C. H., Sun, Q. Y., Wang, F., & Xie, H. N. (2014) · Genetics and Molecular Research · doi:10.4238/2014.october.20.19 · Cited by 19
Neuronal glycogen breakdown mitigates tauopathy via pentose-phosphate-pathway-mediated oxidative stress reduction
Bar, S., Wilson, K. A., Hilsabeck, T. A. U., Alderfer, S. A., Dammer, E. B., Burton, J. B., Shah, S., Holtz, A. N., Carrera, E. M., Beck, J. N., et al. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01314-w · Cited by 20
Clinical Trials: Past, Current, and Future for Atypical Parkinsonian Syndromes
Boxer, A. L., & Tsai, R. M. (2014) · Seminars in Neurology · doi:10.1055/s-0034-1381739 · Cited by 19
A Clinical Approach to Early-Onset Inheritable Dementia
Rogers, B. S., & Lippa, C. F. (2012) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317512444000 · Cited by 19
A model for improving the treatment and care of Alzheimer's disease patients through interdisciplinary research
Trojanowski, J. Q., Arnold, S. E., Karlawish, J. H., Naylor, M. D., Brunden, K. R., & Lee, V. M. ‐. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.08.005 · Cited by 19
Self-citation
The protective role of endogenous n-3 polyunsaturated fatty acids inTauAlzheimer’s disease mouse model
Fang, G., Shi, B., Wu, K., Chen, S., Gao, X., Xiao, S., Kang, J. X., Li, W., & Huang, R. (2018) · International Journal of Neuroscience · doi:10.1080/00207454.2018.1533824 · Cited by 19
Blocking tau transmission by biomimetic graphene nanoparticles
Zhu, R., Makwana, K. M., Zhang, Y., Rajewski, B. H., Valle, J. R. D., & Wang, Y. (2023) · Journal of Materials Chemistry B · doi:10.1039/d3tb00850a · Cited by 18
Potential for Treatment of Neurodegenerative Diseases with Natural Products or Synthetic Compounds that Stabilize Microtubules
Miller, J. H., & Das, V. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200621171302 · Cited by 18
Therapeutic Strategies and Nano-Drug Delivery Applications in Management of Aging Alzheimer’s Disease
Nguyen, T. T., Vo, T. K., & Vo, G. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_13 · Cited by 18
The RNA encoding the microtubule-associated protein tau has extensive structure that affects its biology
Chen, J. L., Moss, W. N., Spencer, A., Zhang, P., Childs‐Disney, J. L., & Disney, M. D. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219210 · Cited by 18
A genetically targeted reporter for PET imaging of deep neuronal circuits in mammalian brains
Shimojo, M., Ono, M., Takuwa, H., Mimura, K., Nagai, Y., Fujinaga, M., Kikuchi, T., Okada, M., Seki, C., Tokunaga, M., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021107757 · Cited by 18
Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH
Killick, R., Hughes, T. R., Morgan, B. P., & Lovestone, S. (2013) · Neuroscience Letters · doi:10.1016/j.neulet.2012.11.008 · Cited by 17
Beneficial Effects of Spirulina on Brain Health: A Systematic Review
Kumar, S., Saha, S., Singh, K., Singh, T., Miahra, A. K., Dubey, B. N., & Singh, S. (2024) · Current Functional Foods · doi:10.2174/0126668629269256231222092721 · Cited by 17
Microtubule stabilization promoted axonal regeneration and functional recovery after spinal root avulsion
Li, H., & Wu, W. (2017) · European Journal of Neuroscience · doi:10.1111/ejn.13585 · Cited by 17
Neuroprotection and improvement of the histopathological and behavioral impairments in a murine Alzheimer’s model treated with Zephyranthes carinata alkaloids
Cortés, N., Sabogal-Guáqueta, A. M., Cardona‐Gómez, G. P., & Osorio, E. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.12.013 · Cited by 17
CNS cell type–specific gene profiling of P301S tau transgenic mice identifies genes dysregulated by progressive tau accumulation
Ke, Y. D., Chan, G., Stefanoska, K., Au, C. G., Bi, M., Müller, J., Przybyla, M., Feiten, A., Prikas, E., Halliday, G. M., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.005263 · Cited by 16
Amyloid beta peptide-degrading microbial enzymes and its implication in drug design
Dhanavade, M. J., & Sonawane, K. D. (2020) · 3 Biotech · doi:10.1007/s13205-020-02240-2 · Cited by 16
ELISA Evaluation of Tau Accumulation in the Brains of Patients with Alzheimer Disease
Shinohara, M., Hirokawa, J., Shimodaira, A., Tashiro, Y., Suzuki, K., Gheni, G., Fukumori, A., Matsubara, T., Morishima, M., Saito, Y., et al. (2021) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlab047 · Cited by 16
Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteome
Plum, S., Steinbach, S., Abel, L., Marcus, K., Helling, S., & May, C. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201400030 · Cited by 16
Frontotemporal lobar degeneration-related proteins induce only subtle memory-related deficits when bilaterally overexpressed in the dorsal hippocampus
Dayton, R. D., Wang, D. B., Cain, C. D., Schrott, L. M., Ramirez, J. J., King, M. A., & Klein, R. L. (2011) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.002 · Cited by 16
New insights on Alzheimer's disease diagnostic.
Fita, I. G., Enciu, A., & Stănoiu, B. (2011) · PubMed · Cited by 16
Pathology of Neurodegenerative Diseases
Kim, Y. S., Kim, Y.-K., Hwang, O., & Dong, J. (2012) · InTech eBooks · doi:10.5772/38028 · Cited by 16
Insights into tau function and dysfunction through single-molecule fluorescence
Melo, A. M., Elbaum‐Garfinkle, S., & Rhoades, E. R. (2017) · Methods in cell biology · doi:10.1016/bs.mcb.2017.06.010 · Cited by 15
Synthesis and biological evaluation of new penta- and heptacyclic indolo- and quinolinocarbazole ring systems obtained via Pd0 catalysed reductive N-heteroannulation
Laronze‐Cochard, M., Cochard, F., Daras, E., Lansiaux, A., Brassart, B., Vanquelef, E., Prost, É., Nuzillard, J., Baldeyrou, B., Goosens, J. F., et al. (2010) · Organic & Biomolecular Chemistry · doi:10.1039/c0ob00149j · Cited by 15
A critical overview of therapeutic strategy and advancement for Alzheimer's disease treatment
Kuo, Y., & Rajesh, R. (2017) · Journal of the Taiwan Institute of Chemical Engineers · doi:10.1016/j.jtice.2017.05.011 · Cited by 15
Synapse maintenance is impacted by ATAT-2 tubulin acetyltransferase activity and the RPM-1 signaling hub
Borgen, M. A., Giles, A. C., Wang, D., & Grill, B. J. (2019) · eLife · doi:10.7554/elife.44040 · Cited by 15
Untangling the Conformational Polymorphism of Disordered Proteins Associated With Neurodegeneration at the Single-Molecule Level
Birol, M., & Melo, A. M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2019.00309 · Cited by 15
Design of Multi-Target drugs of HDACs and other Anti-Alzheimer related Targets: Current strategies and future prospects in Alzheimer’s diseases therapy
Soltan, O. M., Abdelrahman, K. S., Bass, A. K. A., Takizawa, K., Narumi, A., & Konno, H. (2024) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2024.107651 · Cited by 14
Protective role of 6-Hydroxy-1-H-Indazole in an MPTP-induced mouse model of Parkinson's disease
Liang, X., Wen-ting, Z., Xu, Y., Chong-Fa, L., Lu, Z., Jin-jun, R., & Wang, W. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.08.011 · Cited by 14
Tau Pathology Triggered by Spinal Cord Injury Can Play a Critical Role in the Neurotrauma Development
Nakhjiri, E., Vafaee, M. S., Hojjati, S. M. M., Shahabi, P., & Shahpasand, K. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02061-7 · Cited by 14
Amyloid fibril inhibition, acceleration, or fragmentation; Are nano-based approaches advance in the right direction?
Hajipour, M. J., Mohammad‐Beigi, H., Nabipour, I., Mahmoudi, N., Azhdarzadeh, M., Derakhshankhah, H., Dawud, D. E., Mohammadinejad, R., & Otzen, D. E. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100983 · Cited by 14
Asp664 cleavage of amyloid precursor protein induces tau phosphorylation by decreasing protein phosphatase 2A activity
Park, S. S., Jung, H., Kim, Y., Park, T. K., Kim, C., Choi, H., Mook‐Jung, I. H., Koo, E. H., & Park, S. A. (2012) · Journal of Neurochemistry · doi:10.1111/jnc.12032 · Cited by 14

Authors: Brunden, K. R., Trojanowski, J. Q., & Lee, V. M.-Y.
Affiliations: University of Pennsylvania (US)
Corresponding author: Brunden, Kurt R.
ORCID: Brunden, Kurt R.
Trojanowski, John Q.
Lee, Virginia M.-Y.
Venue: Nature Reviews Drug Discovery
Publisher: Springer Science and Business Media LLC
Published: 2009-10
Volume: 8
Issue: 10
Pages: 783-793
ISSN: 1474-1776 (ISSN-L)
1474-1784
DOI: 10.1038/nrd2959
PMC: PMC2787232
OpenAlex: W2021370614
Cited by: 440
References: 140
Citations by year: 2026: 7 · 2025: 12 · 2024: 20 · 2023: 12 · 2022: 17 · 2021: 31 · 2020: 28 · 2019: 23 · 2018: 22 · 2017: 30 · 2016: 30 · 2015: 22 · 2014: 40 · 2013: 31 · 2012: 43
FWCI: 4.24
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
Locations: Nature Reviews Drug Discovery (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (5u01ag024904-10)
National Institute on Aging (U01-AG-024904, P01AG014382, P01 AG11542, P01-AG09215, P30AG10124, P01AG011542, P01 AG-17586, P01AG014449, P01 AG14382, P30AG010124, P01AG009215, P01AG017586, P01 AG14449, UO1 AG24904, U19AG010483, P01-AG19724, P01AG019724)
National Institute of Neurological Disorders and Stroke (P01NS044233)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: tau protein, tauopathy, Alzheimer's disease, tau misfolding, neurodegeneration, tau functions, microtubule-associated proteins
MeSH terms: Alzheimer Disease, Animals, Humans, tau Proteins, Tauopathies, Drug Discovery

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks